Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
2.
Cancer Res ; 35(4): 1093-8, 1975 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1054289

RESUMEN

The effects of six clinically active drugs were tested against a ttansplantable leukemia in inbred strain 2 guinea pigs. Cytoxan and 6-mercaptopurine were found to elicit a therqeutic response against this leukemia based on complete tumor regression of the established tumor as well as a substantial increase in survival time. Animals dying in the untreated control and drug-treated groups revealed typical generalized lymphoblastic leukemia. However, only Cytoxan-treated animals that had relapsed exhibited central nervous system involvement originating from the arachnoid membrane. A tow-drug combination of Cytoxan and 1-(2-chloroethyl)-3(trans-4-methylcyclohexyl)-1-nitrosourea was found not only to prevent meningeal leukemia development but also to result in "curing" all animals from their leukemia. This observation was based on a complete clinical, hematological, and histopathological "remission" period up to 176 days. The administration of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea alone was observed not only to control the systemic leukemia but also to prevent central nervous system involvement. No relapses occurred after the first "remission" period was achieved in the groups of animals that received 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.


Asunto(s)
Antineoplásicos/uso terapéutico , Leucemia Linfoide/tratamiento farmacológico , Animales , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/prevención & control , Ciclohexanos/análogos & derivados , Ciclohexanos/uso terapéutico , Ciclofosfamida/uso terapéutico , Quimioterapia Combinada , Cobayas , Leucemia Experimental/tratamiento farmacológico , Masculino , Meninges , Mercaptopurina/uso terapéutico , Trasplante de Neoplasias , Compuestos de Nitrosourea/uso terapéutico , Prednisolona/uso terapéutico , Remisión Espontánea , Vincristina/uso terapéutico
3.
Cancer ; 35(4): 1148-53, 1975 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1116106

RESUMEN

In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl-CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m2 orally as a single dose every 6 weeks. The dose was subsequently reduced in poor-risk patients to 150 mg/m2. There were 69 responses noted in 675 evaluable patients (10%). The highest response rates were noted in patients with Hodgkin's disease (13/31, 35%), malignant gliomas of the brain (8/29, 28%), anaplastic carcinomas of the lung (5/20, 25%), and squamous cell carcinomas of the head and neck (5/29, 17%). Squamous cell tumors appeared to be more responsive than adenocarcinomas (15% vs. 5%, respectively). Hematologic toxicity was cumulative, and was influenced by dose and prior treatment. There appeared to be no cross-resistance in patients previously treated with alkylating agents. Methyl-CCNU is an active antineoplastic agent. Further studies are indicated in order to determine relative effectiveness.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Compuestos de Nitrosourea/uso terapéutico , Adenocarcinoma/tratamiento farmacológico , Administración Oral , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Neoplasias Encefálicas/tratamiento farmacológico , Carcinoma de Células Escamosas/tratamiento farmacológico , Ciclohexanos/administración & dosificación , Ciclohexanos/análogos & derivados , Ciclohexanos/uso terapéutico , Evaluación de Medicamentos , Resistencia a Medicamentos , Glioma/tratamiento farmacológico , Cabeza , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Compuestos de Nitrosourea/administración & dosificación , Compuestos de Nitrosourea/efectos adversos
4.
Cancer Res ; 35(3): 658-65, 1975 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-234790

RESUMEN

The s.c.-propagated murine glioma, GL-26, was established in tissue culture. The tissue culture line, with a doubling time of 36 hr, was used as the common source for all tumor cells. Suspensions of the tumor cells were transplanted intracerebrally in mice to produce an anaplastic ependymoblastoma. In vitro 51-Cr cytotoxicity assays did not detect any cellular immunity against GL-26 tumor cells in animals bearing either s.c. or i.c. tumors, indicating that the tumor itself is not highly immunogenic. Howeveer,significant cellular cytotoxicity was elicited in non-tumor-bearing animals by immunization with Vibrio cholerae neuramini-animals by immunization with Vibrio cholerae neuraminidase and mitomycin C-treated tumor cells plus complete Freund's adjuvant. In vivo therapy studies revealed significant increases in survival of animals preimmunized with V. cholerae neuraminidase- and mitomycin C-treated cells plus complete Freund's adjuvant. 1(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, when given i.p. on Day 3 or 12 after tumor challenge, also resulted in significant increases in survival. Furthermore, the effects of 1-(2-chloroethyl)- 3-cyclohexyl-1-nitrosourea and preimmunization were additive, with significanchloroethyl)-3-cyclohexyl-1-nitrosourea. In contrast to results reported for several extracranial tumor systems, immunotherapy, using either V.cholerae neuraminidase- and mitomycin-treated tumor cells, Bacillus Calmette-Guerin, or both, beginning 3 0r 4 days after tumor challenge, did not produce any significant increases in survival.


Asunto(s)
Antígenos de Neoplasias , Antineoplásicos/uso terapéutico , Vacuna BCG/uso terapéutico , Neoplasias Encefálicas/terapia , Glioma/terapia , Inmunización , Inmunoterapia , Neuraminidasa/farmacología , Compuestos de Nitrosourea/uso terapéutico , Animales , Técnicas de Cultivo , Ciclohexanos/análogos & derivados , Pruebas Inmunológicas de Citotoxicidad , Ependimoma/terapia , Adyuvante de Freund , Glioma/tratamiento farmacológico , Glioma/inmunología , Inmunidad Celular , Ratones , Ratones Endogámicos C57BL , Mitomicinas/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/terapia
5.
Cancer Res ; 35(3): 568-76, 1975 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-1116123

RESUMEN

Chemical degradation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea or 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea in buffer under physiological conditions resulted in the formation of a significant quantity of 2-chlorethanol (18 to 25% of the initial nitrosourea concentration). Other degradation products observed included acetaldehyde (5 to 10%), vinyl chloride (1 to 2%), ethylene (1 to 2%), and cyclohexylamine (32%), but not 1,3-dicyclohexylurea. The 2-chlorethyl moiety of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea was trapped with halide ions, CI-, BR-, and I-, to form the corresponding dihaloethanes which were identified by gas chromatography-mass spectrometry techniques. High-pressure liquid chromatographic procedures were developed for the separation and quantiation of the nitrosoureas and many of their degradation products. It is postulated that a new mode of 1(2-chloreoethyl)-3-cyclohexyl-1-nitrosourea and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea degradation can occur that is not the loss of the chloro group as chloride ion, but the loss of the N-3 hydrogen as a proton. Then the corresponding isocyanate and 2-chloroethyidiazene hydroxide are formed, with the latter intermidiate becoming an alkylating species, possibly in part as a 2-chloroethyl carbonium ion.


Asunto(s)
Antineoplásicos , Etanol/análogos & derivados , Compuestos de Nitrosourea , Acetaldehído , Alquilación , Fenómenos Químicos , Química , Cloro , Ciclohexanos/análogos & derivados , Ciclohexilaminas , Etilenos , Urea/análogos & derivados , Compuestos de Vinilo
6.
Biochim Biophys Acta ; 380(2): 270-81, 1975 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-1120146

RESUMEN

The drug trans-1,4-bis(2-chlorobenzylaminomethyl)cyclohexane dihydrochloride (AY-9944) almost completely inhibited the conversion of [2-14C] mevalonic acid, dihydro[14C]lanosterol, 4,4-dimethyl-5alpha-[2-3H2]cholesta-8,14-dien-3beta-ol and 4,4-dimethyl-5alpha-[2-3H2]cholest-8(14)-en-3beta-ol to 5alpha-cholest-7-en-3beta-ol and cholesterol by cell-free systems of rat liver. With the first three precursors, the inhibition was accompanied by an accumulation of radioactive 5alpha-cholesta-8,14-dien-3beta-ol, but this material could not be detected during inhibition of cholesterol biosynthesis from 4,4-dimethyl-5alpha-[2-3H2] cholest-8(14)-en-3beta-ol. Regardless of the nature of the precursor, trans-1,4-bis(2-chlorobenzylaminomethyl)cyclohexane dihydrochloride did not result in the accumulation of any delta5,7 sterols. Non-radioactive 5alpha-cholest-8(14)-en-3beta-ol inhibited the conversion of dihydro[14C]lanosterol to 4,4-dimethyl-5alpha-cholesta-8,14-dien-3beta-ol. Carbon monoxide resulted in a decrease in the rate of conversion of dihydro[14C]lanosterol to 4,4-dimethyl-5alpha-cholesta-8,14-dien-3beta-ol but had no effect on the rate of conversion of 4,4-dimethyl-5alpha-[2-3H2]cholesta-8,14-dien-3beta-ol to 5alpha-cholest-7-en-3beta-ol and cholesterol suggesting that cytochrome P-450 is involved neither in the oxidative removal of the 4-methyl groups nor in the oxidative introduction of the delta5 bond during cholesterol biosynthesis. In addition, the process of cholesterol and 5alpha-cholest-7-en-3beta-ol biosynthesis from 4,4-dimethyl-5alpha-[2-3H2]cholest-8(14)-en-3beta-ol was inhibited by carbon monoxide at a stage after the formation of 5alpha-cholest-8(14)-en-3beta-ol.


Asunto(s)
Monóxido de Carbono/farmacología , Colesterol/biosíntesis , Ciclohexanos/análogos & derivados , Hígado/metabolismo , Esteroles/metabolismo , Animales , Compuestos de Bencilo/farmacología , Ciclohexanos/farmacología , Lanosterol/análogos & derivados , Lanosterol/metabolismo , Hígado/efectos de los fármacos , Metilaminas/farmacología , Ácido Mevalónico/metabolismo , Ratas , Relación Estructura-Actividad
9.
Cancer Res ; 35(1): 1-5, 1975 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-162855

RESUMEN

The effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexl-1-nitrosourea, and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea on two nonmitochondrial DNA polymerases (I and II) purified from rat liver and hepatoma were examined. The activity of DNA polymerase I was not altered by treatment with any of the nitrosoureas or the corresponding isocyanates, 2-chloroethyl isocyanate and cyclohexyl isocyanate. Incubation of DNA polymerase II with the nitrosoureas (1 mM) inhibited its enzymatic activity 30 to 45%. DNA polymerase II was inhibited 75 and 90% by 1.mM 2-chloroethyl isocyanate and cyclohexyl isocyanate, respectively. The nitrosoureas appear to exert their inhabitory action on the enzyme (DNA polymerase II) rather than on the DNA template. Pretreatment of the enzyme increased the degree of inhibition by 1 mM nitrosourea (50 to 60% inhibition) or 2-chloroethul isocyanate (greater than 90% inhibition), whereas pretreatment of the DNA template did not enhance the inhibitory effect. The three nitrosoureas are equally effective as inhibitors of DNA polymerase II. 2-Chloroethyl isocyanate and cyclohexyl isocyanate are better inhibitors than are the nitrosoureas. Since further decomposition products of the isocyanates, 2-chloroethylamine and cyclohexylamine, do not inhibit DNA polymerase II, we conclude that the isocyanates, which are decomposition products of the nitrosoureas, are the active inhibitors of the enzyme.


Asunto(s)
Antineoplásicos/farmacología , Carcinoma Hepatocelular/enzimología , Cianatos/farmacología , ADN Nucleotidiltransferasas/antagonistas & inhibidores , Neoplasias Hepáticas/enzimología , Hígado/enzimología , Compuestos de Mostaza/farmacología , Compuestos de Nitrosourea/farmacología , Animales , Carmustina/farmacología , Ciclohexanos/análogos & derivados , Ciclohexanos/farmacología , Ciclohexilaminas , Etilaminas/farmacología , Técnicas In Vitro , Neoplasias Experimentales/enzimología , Ratas , Moldes Genéticos
10.
Invest Urol ; 12(4): 317-9, 1975 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-235500

RESUMEN

Experiments have been conducted which show that while the tertiary amine oxybutynin has only moderate in vitro anticholinergic and antihistaminic activity, it is a potent inhibitor of barium chloride-induced spasms of rabbit detrusor muscle. Oxybutynin exerts 1/13 the anticholinergic activity of propantheline and 1/4 that of atropine, but produces approximately 2x the inhibition of barium chloride-induced spasm than propantheline and 10x the inhibition produced by atropine. In sum, oxybutynin possesses a notable antispasmodic activity distinct from its anticholinergic activity and stronger than that of atropine, propantheline, or methantheline, which may prove useful in the treatment of smooth muscle hypermotility.


Asunto(s)
Bario/antagonistas & inhibidores , Carbacol/antagonistas & inhibidores , Antagonistas de los Receptores Histamínicos H1 , Ácidos Mandélicos/análogos & derivados , Músculo Liso/efectos de los fármacos , Parasimpatolíticos/farmacología , Vejiga Urinaria/efectos de los fármacos , Animales , Atropina/farmacología , Ciclohexanos/análogos & derivados , Ciclohexanos/farmacología , Dietilaminas/farmacología , Evaluación Preclínica de Medicamentos , Masculino , Ácidos Mandélicos/farmacología , Propantelina/farmacología , Compuestos de Amonio Cuaternario/farmacología , Conejos
12.
Lipids ; 10(1): 9-11, 1975 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-1123977

RESUMEN

AY-994 (trans-1,4-bis-(2-chlorobenzyl-aminomethyl) cyclohexane dihydrochloride), a potent inhibitor of the enzymatic reduction of the delta 7-double bond of delta 5,7-sterols, has been shown to inhibit, at higher concentrations (10-4 M), the enzymatic reduction of the delta 14-double bond of cholesta-8,14-dien-3 beta-ol and cholesta-7,14-dien-3 beta-ol.


Asunto(s)
Colestadienoles/metabolismo , Ciclohexanos/análogos & derivados , Hígado/enzimología , Oxidorreductasas/antagonistas & inhibidores , Animales , Compuestos de Bencilo/farmacología , Cloro/farmacología , Ciclohexanos/farmacología , Femenino , Hígado/efectos de los fármacos , Metilaminas/farmacología , Oxidación-Reducción , Ratas , Relación Estructura-Actividad
14.
J Natl Cancer Inst ; 54(1): 69-71, 1975 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-1117460

RESUMEN

In a randomized, controlled study of 80 patients with advanced colorectal carcinoma, the combination of 5-fluorouracil (5-FU), methyl-1, 3-cis(2-chlorethyl)-1-nitrosourea, and vincristine produced an overall degree to toxicity comparable to that of 5-FU used alone. At 10 weeks, a positive objective response rate of 43.5% was observed with the three-drug combination compared to 19.5% with 5-FU alone (P less than 0.5).


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias del Colon/tratamiento farmacológico , Fluorouracilo/uso terapéutico , Compuestos de Nitrosourea/uso terapéutico , Neoplasias del Recto/tratamiento farmacológico , Vincristina/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Ciclohexanos/efectos adversos , Ciclohexanos/análogos & derivados , Ciclohexanos/uso terapéutico , Estudios de Evaluación como Asunto , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Compuestos de Nitrosourea/administración & dosificación , Compuestos de Nitrosourea/efectos adversos , Vincristina/administración & dosificación , Vincristina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA